Nicolas Gendron on TITAN’s Recent Study: Insights on Managing Pregnancy in Antithrombin Deficiency
Nicolas Gendron, Research Fellow, Hematologist at Boston Children’s Hospital, shared a proud post on LinkedIn:
‘‘Pregnancy and Antithrombine Deficiency
We are very pleased to announce the online publication of our French recommendations on the management of pregnancy in women with congenital antithrombin deficiency (ATD), published in Thromb Haemost (Thrombosis Haemostasis Journal).
Congenital antithrombin deficiency is a rare condition but is associated with a major thromboembolic risk, particularly in the context of pregnancy.
Given the limited literature and heterogeneous international recommendations, the Thrombosis, Anticoagulants, and Antiplatelet Agents (TITAN) group of the French Society for Thrombosis and Hemostasis (SFTH) conducted an in-depth review of the literature in order to propose concrete elements to aid decision-making.
These proposals address:
- The indication and dosage regimen for anticoagulants
- Relevant biological monitoring
- The role of antithrombin concentrates during and at the end of pregnancy
- The crucial importance of multidisciplinary coordination between hematologists, obstetricians, and anesthesiologists.
Read the full article here.
Congratulations to all the co-authors for this collective work! Special thanks to Laurent for leading the project.
Mauge Laetitia, Hugo Madar, Julie Carré, Mathieu Fiore, Christine Mouton, Valérie Proulle, Suchon Pierre, Nathalie Trillot, Thomas Lechat, Loïc Sentilhes and Laurent Macchi.”
Article: How to Manage Venous Thromboembolism Risk during Pregnancy in Patients with Inherited Antithrombin Deficiency?
Authors: Laetitia Mauge , Hugo Madar, Julie Carré, Mathieu Fiore, Nicolas Gendron, Christine Mouton, Valérie Proulle, Pierre Suchon, Nathalie Trillot, Thomas Lechat, Loïc Sentilhes, Laurent Macchi, On behalf of the TITAN group of the French Society of Thrombosis and Haemostasis (SFTH)
Stay updated on the latest scientific advancements in the field of hemostasis and thrombosis with Hemostasis Today.
-
Aug 4, 2025, 17:06Nathan Connell and John Fanikos Invite You to the Vasculearn Network Podcast
-
Aug 4, 2025, 16:44Honoring Visionary Leadership in Hemophilia Care: A Tribute to Drs. Cesar Garrido and Assad Haffar
-
Aug 4, 2025, 14:54Shreyas Kalantri: Engaging Insights on VTE Management
-
Aug 4, 2025, 06:00Genotype–Phenotype Understanding in Hemophilia B: Commentary on Factor IX Missense Variants
-
Aug 4, 2025, 05:47National Health Center Week – Recognizing the Vital Role of HTCs in Specialized Care
-
Aug 4, 2025, 17:29MADD: First Causal Gene for Quantitative Von Willebrand Disease Discovered
-
Aug 4, 2025, 16:13Nicolas Gendron on TITAN’s Recent Study: Insights on Managing Pregnancy in Antithrombin Deficiency
-
Aug 4, 2025, 01:59Michael Makris Posts Haemophilia Journal Article Reassessing UK Blood Inquiry
-
Aug 4, 2025, 01:09Manuel Monreal Congratulates Authors Ahead of JTH Publication: VTE-Predict Score Validated in RIETE Cohort
-
Aug 3, 2025, 17:48Nathan Connell: What Is The "Mild Equivalent" For Hemophilia A That Is Achieved While on Emicizumab?
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Aug 4, 2025, 05:20NBCA: Alexis’s DVT Diagnosis Came Without Warning - Learn How She Caught It Early
-
Aug 4, 2025, 00:50NBCA: After Losing Her Daughter to a Blood Clot, Charita Fights to Save Others
-
Aug 3, 2025, 18:10Andrew Agwunobi Congrats Dr. Oladipo Cole and The Whole Team at the Connecticut Bleeding Disorder Center
-
Aug 3, 2025, 12:03Elias Bouchi Presents Werfen EEMEA Talks on Hemostasis: Clot Stories Season 3
-
Jul 31, 2025, 15:37Sano Genetics: “Unreasonable” Leadership with Benny Sorenson of Hemab